Tonix Pharmaceuticals Holding Corp. (TNXP)
2.38
-0.17
(-6.67%)
USD |
NASDAQ |
Nov 20, 16:00
2.39
+0.01
(+0.42%)
After-Hours: 20:00
Tonix Pharmaceuticals Research and Development Expense (TTM) : 80.40M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 80.40M |
| June 30, 2026 | 63.86M |
| March 31, 2026 | 55.26M |
| December 31, 2025 | 44.49M |
| September 30, 2025 | 35.84M |
| June 30, 2025 | 35.67M |
| March 31, 2025 | 34.54M |
| December 31, 2024 | 39.97M |
| September 30, 2024 | 48.80M |
| June 30, 2024 | 60.73M |
| March 31, 2024 | 73.01M |
| December 31, 2023 | 86.66M |
| September 30, 2023 | 94.21M |
| June 30, 2023 | 95.36M |
| March 31, 2023 | 89.96M |
| December 31, 2022 | 81.88M |
| September 30, 2022 | 79.50M |
| June 30, 2022 | 70.38M |
| March 31, 2022 | 71.93M |
| December 31, 2021 | 68.84M |
| September 30, 2021 | 58.64M |
| June 30, 2021 | 54.37M |
| March 31, 2021 | 46.81M |
| December 31, 2020 | 36.16M |
| September 30, 2020 | 29.75M |
| Date | Value |
|---|---|
| June 30, 2020 | 25.99M |
| March 31, 2020 | 18.97M |
| December 31, 2019 | 18.19M |
| September 30, 2019 | 17.56M |
| June 30, 2019 | 15.77M |
| March 31, 2019 | 16.28M |
| December 31, 2018 | 17.56M |
| September 30, 2018 | 16.14M |
| June 30, 2018 | 16.78M |
| March 31, 2018 | 15.52M |
| December 31, 2017 | 13.34M |
| September 30, 2017 | 14.59M |
| June 30, 2017 | 16.15M |
| March 31, 2017 | 20.86M |
| December 31, 2016 | 28.53M |
| September 30, 2016 | 33.14M |
| June 30, 2016 | 37.99M |
| March 31, 2016 | 39.35M |
| December 31, 2015 | 35.50M |
| September 30, 2015 | 31.79M |
| June 30, 2015 | 26.69M |
| March 31, 2015 | 21.90M |
| December 31, 2014 | 18.62M |
| September 30, 2014 | 14.17M |
| June 30, 2014 | 10.59M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Heron Therapeutics, Inc. | 11.93M |
| Ionis Pharmaceuticals, Inc. | 921.08M |
| TG Therapeutics, Inc. | 236.22M |
| Karyopharm Therapeutics, Inc. | 120.81M |
| Minerva Neurosciences, Inc. | 19.77M |